CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
Masimo to Present in the Jefferies London Healthcare Conference
Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at A replay of the webcast will be available following the live presentation.
Merck to Participate in the Jefferies London Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and head of oncology,
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
AC Immune to Present at the Jefferies 2024 London Healthcare ConferenceLausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a
Korro to Present at the Jefferies London Healthcare Conference
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit.
Aurinia to Participate in Jefferies London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024.
Business Insider2d
Positive Outlook on Crispr Therapeutics AG Driven by Strong Pricing and Strategic Partnerships
Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...
ETF Daily News3d
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $74.94 Consensus Price Target from Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports.
Is CRISPR Therapeutics (CRSP) a Promising Gene Editing Stock?
We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...
Yahoo Finance6d
CRISPR Therapeutics AG (CRSP)
ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?
In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other ...
ETF Daily News15d
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by PFG Investments LLC
PFG Investments LLC lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.3% during the third quarter, according to its most recent disclosure with the ...